Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Perjeta (Pertuzumab) Market Expected to Grow Between 2025 And 2029?
In the past few years, the market size for Perjeta (Pertuzumab) has seen a prominent surge. The market, which stands at $935.92 million in 2024, is projected to expand to $1,084.80 million in 2025, showcasing a compound annual growth rate (CAGR) of 15.9%. The historical growth of this market is linked with factors such as enhanced usage in oncology, increased demand for Antibody-drug Conjugates (ADCs), preference for less toxic and targeted treatments, augmented inorganic growth, and the surging demand for personalized and targeted medication.
What Growth Rate Is Anticipated for the Perjeta (Pertuzumab) Market in the Coming Years?
Expectations are high for the pertuzumab (perjeta) market to experience a swift expansion in the upcoming years. The projection suggests a growth to $1,932.66 million by 2029, following a compound annual growth rate (CAGR) of 15.5%. Factors contributing to this projected growth during the forecast period include an uptick in breast cancer cases, heightened focus on ADCs for hematologic malignancies, an increase in overall cancer incidences, unfulfilled medical requirements, and an upsurge in pharmaceutical research and development for cancer immunotherapy. The forecast period is also anticipated to witness trending adoption of biosimilars in oncology, development of biosimilars and generic drugs, innovation in drug formation, advancements in cancer immunotherapy studies, and a notable rise in combination therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19917&type=smp
Who Are the Leading Companies in the Perjeta (Pertuzumab) Market?
Major companies operating in the perjeta (pertuzumab) market include Roche Holding AG
What Are the Key Drivers of the Perjeta (Pertuzumab) Market?
The expanding prevalence of breast cancer is anticipated to spur the growth of the Perjeta (pertuzumab) market. This condition is characterized by the formation of malignant cells in the breast tissue, often initiating from the ducts or lobules. The surge in breast cancer cases has been linked to lifestyle alterations such as increased obesity and stagnant habits, complemented by enhanced early detection through comprehensive screening programs. Perjeta (pertuzumab) is employed to address HER2-positive breast cancer by targeting the HER2 receptor and is usually mixed with trastuzumab and chemotherapy to improve treatment results. For instance, in October 2023, Ray of Light Wales, a UK charity organization, estimated that the number of UK residents who have had a breast cancer diagnosis is about 600,000 and is expected to reach 1.2 million by 2030. Hence, the escalating prevalence of breast cancer fuels the growth of the herceptin biosimilars market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19917&type=smp
What Are the Key Market Segments in the Perjeta (Pertuzumab) Industry?
The perjeta (pertuzumab)market covered in this report is segmented –
1) By Type: Human source; Animal source
2) By Product: Monoclonal Antibody; Biologic Drug
3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
What Are the Latest Trends in the Perjeta (Pertuzumab) Market?
The prevailing trend in the Perjeta (pertuzumab) market is directed towards the invention of cutting-edge solutions like subcutaneous combination treatments. This is aimed at enhancing patient prognosis and the convenience of treatment. Subcutaneous combination therapies denote treating methods in which at least two drugs are combined in a single injection delivered under the skin to cure a specific condition. In November 2023, for example, Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer, was launched by Chugai Pharmaceutical Co., Ltd., a pharmaceutical company in Japan. This revolutionary treatment for subcutaneous application merges pertuzumab and trastuzumab monoclonal antibodies with vorhyaluronidase alfa, enabling administration in only 5 to 8 minutes, which markedly reduces the time against traditional intravenous infusions. Phesgo is provided for patients with advanced or recurrent HER2-positive colorectal cancer and is the first subcutaneous option for treating this condition.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/perjeta-pertuzumab-global-market-report
What Are the Key Regional Markets in the Perjeta (Pertuzumab) Industry?
North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19917
This Report Delivers Insight On:
1. How big is the perjeta (pertuzumab) market, and how is it changing globally?
2. Who are the major companies in the perjeta (pertuzumab) market, and how are they performing?
3. What are the key opportunities and risks in the perjeta (pertuzumab) market right now?
4. Which products or customer segments are growing the most in the perjeta (pertuzumab) market?
5. What factors are helping or slowing down the growth of the perjeta (pertuzumab) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model